Heartland Advisors Inc. Has $4.02 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Heartland Advisors Inc. increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 41.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,376 shares of the company’s stock after acquiring an additional 18,851 shares during the period. Heartland Advisors Inc.’s holdings in Prestige Consumer Healthcare were worth $4,017,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PBH. Norges Bank bought a new stake in Prestige Consumer Healthcare during the second quarter valued at $41,848,000. Tributary Capital Management LLC increased its stake in Prestige Consumer Healthcare by 157.3% in the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock worth $23,675,000 after purchasing an additional 231,969 shares during the period. Edgestream Partners L.P. bought a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at $10,821,000. Neumeier Poma Investment Counsel LLC increased its holdings in Prestige Consumer Healthcare by 119.5% during the 2nd quarter. Neumeier Poma Investment Counsel LLC now owns 222,495 shares of the company’s stock valued at $17,766,000 after purchasing an additional 121,145 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on PBH shares. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Oppenheimer lowered their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $80.60.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 2,000 shares of company stock worth $125,930. Insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.7%

Shares of PBH opened at $66.32 on Wednesday. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $3.14 billion, a P/E ratio of 17.55, a PEG ratio of 2.10 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a twelve month low of $57.25 and a twelve month high of $90.04. The firm’s 50-day moving average is $64.07 and its two-hundred day moving average is $63.45.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the prior year, the company earned $1.22 earnings per share. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).